BLS Pharmaceuticals（BLS）株式概要ライフサイエンスと消費者向け健康製品の会社であるBioxyne Limitedは、消費者向け健康製品、特許取得済みプロバイオティクス、健康サプリメント、治療用品、代替医薬品の製造と販売に従事している。 詳細BLS ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績5/6財務の健全性5/6配当金0/6報酬株価収益率（ 21.8 x）は、 Life Sciences業界平均（ 36.3 x）を下回っています。過去1年間で収益は244.8%増加しました リスク分析高いレベルの非現金収入 Australian市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るBLS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW478,741 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA478,741 investors already sharing narrativesYour Fair ValueAU$Current PriceAU$0.9685.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-13m612m2016201920222025202620282031Revenue AU$611.6mEarnings AU$113.8mAdvancedSet Fair ValueView all narrativesBLS Pharmaceuticals Limited 競合他社CryositeSymbol: ASX:CTEMarket cap: AU$58.6mAroa BiosurgerySymbol: ASX:ARXMarket cap: AU$195.4mVita Life SciencesSymbol: ASX:VLSMarket cap: AU$137.0mClinuvel PharmaceuticalsSymbol: ASX:CUVMarket cap: AU$498.2m価格と性能株価の高値、安値、推移の概要BLS Pharmaceuticals過去の株価現在の株価AU$0.9652週高値AU$1.1052週安値AU$0.33ベータ0.651ヶ月の変化-4.00%3ヶ月変化47.69%1年変化95.92%3年間の変化405.26%5年間の変化220.00%IPOからの変化190.92%最新ニュースNew Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026最新情報をもっと見るRecent updatesNew Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026Board Change • Dec 31Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Non-Executive Independent Chairman Tony Ho is the most experienced director on the board, commencing their role in 2012. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • Dec 16Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 28Bioxyne Limited, Annual General Meeting, Nov 26, 2025Bioxyne Limited, Annual General Meeting, Nov 26, 2025. Location: at addisons level 9, 2 park street, sydney nsw 2000 AustraliaReported Earnings • Aug 31Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024)Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$30.4m (up 216% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 16% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Aug 18Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Non-Executive Independent Chairman Tony Ho is the most experienced director on the board, commencing their role in 2012. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • Jul 23Bioxyne Limited to Report Q4, 2025 Results on Jul 28, 2025Bioxyne Limited announced that they will report Q4, 2025 results on Jul 28, 2025お知らせ • Apr 03Bioxyne Limited Appoints Michael Barnes to Its Advisory BoardBioxyne Limited (BXN) announced that leading consultant neurologist, Professor Michael Barnes MD. FRCP ("Mike" or "Prof Barnes"), president of the Cannabis Industry Council, president of the Medical Cannabis Clinicians Society (UK) has joined the BXN advisory board. Prof Barnes will advise the Company as it develops its medicinal cannabis business in the UK. Prof Barnes was previously an advisor to GW Pharmaceuticals. The Company will also leverage Prof Barnes's experience in registering medicines for marketing authorization, which will allow it to distribute its products through traditional prescriber channels, without the need for special access or authorized prescriber pathways. Author of more than a dozen authoritative books and 100 academic papers, Prof. Barnes has dedicated the latter part of his career to the development of medical cannabis awareness, education and clinical excellence. He brings his expertise to global medical cannabis organisations, educates clinicians and patients and advocates for a pragmatic and robust approach to medical cannabis prescribing as the UK industry growth. In 2018, Prof. Barnes was the first UK doctor to successfully negotiate a medical cannabis prescription from the Government, for Alfie Dingley. Prof Barnes was the Founder Chair of the Medical Cannabis Clinicians Society, a not-for-profit society providing training, expert guidance & peer support for clinicians prescribing life- changing medical cannabis treatments in the UK. He also is chair of the Cannabis Industry Council. As Honorary President of the Cannabis Industry Council and the Medical Cannabis Clinicians Society, Mike is connected with every medical cannabis prescriber and clinic in the UK. He also advises government on legislation relating to the medical cannabis industry. As a consultant neurologist and medical cannabis expert, Professor Mike Barnes has dedicated his career to the development of neurological rehabilitation and medical cannabis treatments and education. Over 30 years within senior roles in the NHS and independent neurorehabilitation services, Professor Barnes became interested in the medical applications of cannabis with the progression of Sativex to market. He signed off an expert report to the Medicines and Healthcare products Regulatory Agency which was subsequently used, with more recent evidence, to establish Sativex - a cannabis extract which alleviates symptoms of multiple sclerosis - in over 30 countries.お知らせ • Mar 21Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct ListingBoard Change • Feb 04Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 23Bioxyne Limited Upgrades Revenue Guidance for the Year Ended 30 June 2025Bioxyne Limited advised that its upgraded Revenue forecast for the year ended 30 June 2025 is increased to $25,000,000.Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 04Bioxyne Limited, Annual General Meeting, Nov 21, 2024Bioxyne Limited, Annual General Meeting, Nov 21, 2024.Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.64m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.64m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.66m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.お知らせ • Apr 23Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listingお知らせ • Apr 18Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct ListingNew Risk • Apr 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Market cap is less than US$10m (AU$15.2m market cap, or US$9.86m).New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Shares are highly illiquid. Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$20.9m market cap, or US$13.6m).Board Change • Jan 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO, MD & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO, MD & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 17Bioxyne Limited Announces Retirement of N H Chua as DirectorBioxyne Limited announced that Mr. N H Chua has retired from the Board following the Annual General Meeting that was held 17 November 2023. Sam Watson will continue as sole Chief Executive Officer and Managing Director.Board Change • Oct 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 05Bioxyne Limited, Annual General Meeting, Nov 17, 2023Bioxyne Limited, Annual General Meeting, Nov 17, 2023, at 10:00 AUS Eastern Standard Time.Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)Full year 2023 results: AU$0.001 loss per share (in line with FY 2022). Revenue: AU$5.30m (up AU$4.84m from FY 2022). Net loss: AU$1.94m (loss widened 293% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Board Change • Oct 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Sep 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0.002 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0.002. Revenue: AU$5.34m (up 115% from FY 2022). Net loss: AU$1.94m (loss widened AU$1.70m from FY 2022).New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$2.3m revenue, or US$1.5m). Market cap is less than US$100m (AU$22.8m market cap, or US$14.6m).Board Change • Jul 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jun 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 24Bioxyne Limited Appoints Jason Hine as DirectorBioxyne Limited announced that the appointment of Jason Hine as director of the company with effect from May 19, 2023.お知らせ • May 23Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd.Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals. On March 20, 2023, Bioxyne executed the long form Sale and Purchase Agreement with BLS’ majority shareholders. Completed due diligence confirms the synergies between the Bioxyne and BLS. The Bioxyne and BLS have commenced formulating a combined business development growth strategy for post-acquisition. Other conditions precedent to completion include, The remaining minority BLS shareholders acceding as parties to the SPA, New employment agreements for key BLS employees, including appropriate restraints and No material adverse change occurring in relation to Breathe Life Sciences. BXN and BLS will work together, in good faith, to satisfy the remaining conditions precedent by May 31, 2023 to implement the proposed transaction. If the conditions precedent are not satisfied (or waived) by this date, then unless the Long Stop Date is extended by agreement, either party may terminate the SPA and the proposed transaction. As of May 5, 2023, Bioxyne received shareholder approval for the acquisition of BLS.Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd on May 22, 2022. Bioxyne has completed the acquisition of Breathe Life Sciences following shareholder approval, due diligence and the satisfaction of all conditions precedent. BLS's Sam Watson (Chief Executive Officer) and Jason Hine (Chief Operating Officer) will be appointed to the Board of Directors.Board Change • May 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 24First half 2023 earnings releasedFirst half 2023 results: Revenue: AU$1.28m (down 9.9% from 1H 2022). Net income: AU$23.2k (up 409% from 1H 2022). Profit margin: 1.8% (up from 0.3% in 1H 2022). The increase in margin was driven by lower expenses.Board Change • Jan 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 03Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)Full year 2022 results: EPS: AU$0 (up from AU$0.001 loss in FY 2021). Revenue: AU$2.52m (up 14% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Board Change • Sep 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jun 28No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Mar 22No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Feb 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jan 06No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Dec 22No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 09No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Oct 04Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.20m (down 5.6% from FY 2020). Net loss: AU$495.7k (loss narrowed 16% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.22m (down 4.3% from FY 2020). Net loss: AU$425.7k (loss narrowed 28% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Reported Earnings • Oct 03Full year earnings released - AU$0.00093 loss per shareOver the last 12 months the company has reported total losses of AU$593.1k, with losses narrowing by 53% from the prior year. Total revenue was AU$2.32m over the last 12 months, up 5.4% from the prior year.株主還元BLSAU Life SciencesAU 市場7D0%-8.0%-0.3%1Y95.9%4.3%0.05%株主還元を見る業界別リターン: BLS過去 1 年間で4.3 % の収益を上げたAustralian Life Sciences業界を上回りました。リターン対市場: BLS過去 1 年間で0.1 % の収益を上げたAustralian市場を上回りました。価格変動Is BLS's price volatile compared to industry and market?BLS volatilityBLS Average Weekly Movement14.7%Life Sciences Industry Average Movement18.3%Market Average Movement9.6%10% most volatile stocks in AU Market16.6%10% least volatile stocks in AU Market3.8%安定した株価: BLSの株価は、 Australian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: BLSの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてAustralianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1998n/aSam Watsonblspharma.comライフサイエンスと消費者向け健康製品の会社であるBioxyne Limitedは、消費者向け健康製品、特許取得済みプロバイオティクス、健康サプリメント、治療用品、代替医薬品の製造と販売に従事している。同社は、カンナビノイド、カンナビスエキス、カンナビスパスティーユ、THCフラワー、ベイプ、オーラルリキッド、向精神薬、スキンケア製品、キノコ複合体など、植物由来のウェルネス製品やサプリメントを製造、商品化、販売している。また、市販の腸内健康免疫サプリメント製品用の乳酸菌VRI-003など、様々な機能性食品も開発している。さらに、製品の研究開発サービスや遠隔医療サービスも提供している。さらに、遠隔医療プラットフォームであるBLS Clinicsや、スポンサー、製造業者、栽培業者、薬局が交流し、CoCを管理し、規制された環境でバルク出発原料、API、完成品を売買するための機械学習主導のB2B技術プラットフォームであるCanXChange Australiaを運営している。同社はDr Watson、Mirai Solution、Apothecary CBDブランドで製品を提供している。同社はオンラインで製品を提供するほか、オーストラリア、米国、英国、日本、チェコ、スイス、フランス、ドイツで卸売りや直接販売を行っている。同社は1998年に法人化され、オーストラリアのシドニーに本社を置いている。もっと見るBLS Pharmaceuticals Limited 基礎のまとめBLS Pharmaceuticals の収益と売上を時価総額と比較するとどうか。BLS 基礎統計学時価総額AU$196.63m収益（TTM）AU$8.92m売上高(TTM)AU$47.95m21.8xPER（株価収益率4.1xP/SレシオBLS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BLS 損益計算書（TTM）収益AU$47.95m売上原価AU$28.27m売上総利益AU$19.69mその他の費用AU$10.77m収益AU$8.92m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.039グロス・マージン41.05%純利益率18.60%有利子負債／自己資本比率13.6%BLS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 13:50終値2026/07/14 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BLS Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).
お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026
New Risk • Jun 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$22.7m (US$15.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (AU$22.7m market cap, or US$15.7m).
お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • May 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (87% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
Board Change • May 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026
Board Change • Dec 31Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Non-Executive Independent Chairman Tony Ho is the most experienced director on the board, commencing their role in 2012. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • Dec 16Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 28Bioxyne Limited, Annual General Meeting, Nov 26, 2025Bioxyne Limited, Annual General Meeting, Nov 26, 2025. Location: at addisons level 9, 2 park street, sydney nsw 2000 Australia
Reported Earnings • Aug 31Full year 2025 earnings released: EPS: AU$0.002 (vs AU$0.007 loss in FY 2024)Full year 2025 results: EPS: AU$0.002 (up from AU$0.007 loss in FY 2024). Revenue: AU$30.4m (up 216% from FY 2024). Net income: AU$4.90m (up AU$17.7m from FY 2024). Profit margin: 16% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Aug 18Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Non-Executive Independent Chairman Tony Ho is the most experienced director on the board, commencing their role in 2012. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • Jul 23Bioxyne Limited to Report Q4, 2025 Results on Jul 28, 2025Bioxyne Limited announced that they will report Q4, 2025 results on Jul 28, 2025
お知らせ • Apr 03Bioxyne Limited Appoints Michael Barnes to Its Advisory BoardBioxyne Limited (BXN) announced that leading consultant neurologist, Professor Michael Barnes MD. FRCP ("Mike" or "Prof Barnes"), president of the Cannabis Industry Council, president of the Medical Cannabis Clinicians Society (UK) has joined the BXN advisory board. Prof Barnes will advise the Company as it develops its medicinal cannabis business in the UK. Prof Barnes was previously an advisor to GW Pharmaceuticals. The Company will also leverage Prof Barnes's experience in registering medicines for marketing authorization, which will allow it to distribute its products through traditional prescriber channels, without the need for special access or authorized prescriber pathways. Author of more than a dozen authoritative books and 100 academic papers, Prof. Barnes has dedicated the latter part of his career to the development of medical cannabis awareness, education and clinical excellence. He brings his expertise to global medical cannabis organisations, educates clinicians and patients and advocates for a pragmatic and robust approach to medical cannabis prescribing as the UK industry growth. In 2018, Prof. Barnes was the first UK doctor to successfully negotiate a medical cannabis prescription from the Government, for Alfie Dingley. Prof Barnes was the Founder Chair of the Medical Cannabis Clinicians Society, a not-for-profit society providing training, expert guidance & peer support for clinicians prescribing life- changing medical cannabis treatments in the UK. He also is chair of the Cannabis Industry Council. As Honorary President of the Cannabis Industry Council and the Medical Cannabis Clinicians Society, Mike is connected with every medical cannabis prescriber and clinic in the UK. He also advises government on legislation relating to the medical cannabis industry. As a consultant neurologist and medical cannabis expert, Professor Mike Barnes has dedicated his career to the development of neurological rehabilitation and medical cannabis treatments and education. Over 30 years within senior roles in the NHS and independent neurorehabilitation services, Professor Barnes became interested in the medical applications of cannabis with the progression of Sativex to market. He signed off an expert report to the Medicines and Healthcare products Regulatory Agency which was subsequently used, with more recent evidence, to establish Sativex - a cannabis extract which alleviates symptoms of multiple sclerosis - in over 30 countries.
お知らせ • Mar 21Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
Board Change • Feb 04Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 23Bioxyne Limited Upgrades Revenue Guidance for the Year Ended 30 June 2025Bioxyne Limited advised that its upgraded Revenue forecast for the year ended 30 June 2025 is increased to $25,000,000.
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 04Bioxyne Limited, Annual General Meeting, Nov 21, 2024Bioxyne Limited, Annual General Meeting, Nov 21, 2024.
Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.64m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.64m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.007 loss per share (vs AU$0.001 loss in FY 2023)Full year 2024 results: AU$0.007 loss per share (further deteriorated from AU$0.001 loss in FY 2023). Revenue: AU$9.66m (up 82% from FY 2023). Net loss: AU$12.8m (loss widened AU$10.9m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 23Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
お知らせ • Apr 18Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million.Bioxyne Limited has filed a Follow-on Equity Offering in the amount of AUD 1.45 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 145,000,000 Price\Range: AUD 0.01 Transaction Features: Subsequent Direct Listing
New Risk • Apr 15New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$15.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Market cap is less than US$10m (AU$15.2m market cap, or US$9.86m).
New Risk • Mar 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.4m free cash flow). Shares are highly illiquid. Earnings have declined by 55% per year over the past 5 years. Shareholders have been substantially diluted in the past year (186% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$20.9m market cap, or US$13.6m).
Board Change • Jan 09No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO, MD & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. CEO, MD & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 17Bioxyne Limited Announces Retirement of N H Chua as DirectorBioxyne Limited announced that Mr. N H Chua has retired from the Board following the Annual General Meeting that was held 17 November 2023. Sam Watson will continue as sole Chief Executive Officer and Managing Director.
Board Change • Oct 31No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 05Bioxyne Limited, Annual General Meeting, Nov 17, 2023Bioxyne Limited, Annual General Meeting, Nov 17, 2023, at 10:00 AUS Eastern Standard Time.
Reported Earnings • Oct 05Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)Full year 2023 results: AU$0.001 loss per share (in line with FY 2022). Revenue: AU$5.30m (up AU$4.84m from FY 2022). Net loss: AU$1.94m (loss widened 293% from FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Board Change • Oct 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Sep 18No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 01Full year 2023 earnings released: EPS: AU$0.002 (vs AU$0 in FY 2022)Full year 2023 results: EPS: AU$0.002. Revenue: AU$5.34m (up 115% from FY 2022). Net loss: AU$1.94m (loss widened AU$1.70m from FY 2022).
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Shareholders have been substantially diluted in the past year (197% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$2.3m revenue, or US$1.5m). Market cap is less than US$100m (AU$22.8m market cap, or US$14.6m).
Board Change • Jul 14No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jun 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Joint CEO & Executive Director Sam Watson was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 24Bioxyne Limited Appoints Jason Hine as DirectorBioxyne Limited announced that the appointment of Jason Hine as director of the company with effect from May 19, 2023.
お知らせ • May 23Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd.Bioxyne Limited (ASX:BXN) entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million on December 19, 2022. As per the terms, Bioxyne Limited will issue 1,230,000,000 shares as a consideration. Transaction is subject to conditions precedent including due diligence, all BLS shareholders entering into binding long form share sale agreements, Shareholder, any necessary regulatory and third party approvals. On March 20, 2023, Bioxyne executed the long form Sale and Purchase Agreement with BLS’ majority shareholders. Completed due diligence confirms the synergies between the Bioxyne and BLS. The Bioxyne and BLS have commenced formulating a combined business development growth strategy for post-acquisition. Other conditions precedent to completion include, The remaining minority BLS shareholders acceding as parties to the SPA, New employment agreements for key BLS employees, including appropriate restraints and No material adverse change occurring in relation to Breathe Life Sciences. BXN and BLS will work together, in good faith, to satisfy the remaining conditions precedent by May 31, 2023 to implement the proposed transaction. If the conditions precedent are not satisfied (or waived) by this date, then unless the Long Stop Date is extended by agreement, either party may terminate the SPA and the proposed transaction. As of May 5, 2023, Bioxyne received shareholder approval for the acquisition of BLS.Bioxyne Limited (ASX:BXN) completed the acquisition of Breathe Life Sciences Pty Ltd on May 22, 2022. Bioxyne has completed the acquisition of Breathe Life Sciences following shareholder approval, due diligence and the satisfaction of all conditions precedent. BLS's Sam Watson (Chief Executive Officer) and Jason Hine (Chief Operating Officer) will be appointed to the Board of Directors.
Board Change • May 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 24First half 2023 earnings releasedFirst half 2023 results: Revenue: AU$1.28m (down 9.9% from 1H 2022). Net income: AU$23.2k (up 409% from 1H 2022). Profit margin: 1.8% (up from 0.3% in 1H 2022). The increase in margin was driven by lower expenses.
Board Change • Jan 13No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 28No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 11No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 03Full year 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in FY 2021)Full year 2022 results: EPS: AU$0 (up from AU$0.001 loss in FY 2021). Revenue: AU$2.52m (up 14% from FY 2021). Net loss: AU$236.5k (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Board Change • Sep 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 23No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CFO, Company Secretary & Executive Director Guy Robertson was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jun 28No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Mar 22No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Feb 02No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jan 06No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Dec 22No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 09No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Peter Hughes-Hallett was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 04Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.20m (down 5.6% from FY 2020). Net loss: AU$495.7k (loss narrowed 16% from FY 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 02Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2021 results: Revenue: AU$2.22m (down 4.3% from FY 2020). Net loss: AU$425.7k (loss narrowed 28% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Oct 03Full year earnings released - AU$0.00093 loss per shareOver the last 12 months the company has reported total losses of AU$593.1k, with losses narrowing by 53% from the prior year. Total revenue was AU$2.32m over the last 12 months, up 5.4% from the prior year.
